ESMO Breast 2023 | Development of antibody-drug conjugate therapies in breast cancer

Heather McArthur, MD, UT Southwestern Medical Center, Dallas, TX, discusses the current state of the art regarding the use of antibody-drug conjugates in breast cancer, highlighting developments such as trastuzumab emtansine (TDM1), sacituzumab govetican, and trastuzumab deruxtecan (T-DXd). This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.